ArticleEJNMMI research2021
The prognostic significance of [
Article in EJNMMI research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The [European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Automated Deauville Score computation from baseline [¹⁸F]FDG PET/CT predicts progression-free survival in multiple myeloma: a radiogenomic framework.European journal of nuclear medicine and molecular imaging · 2026Article
- Review
- Triple-tracer PET (Scientific reports · 2026Article
- Correlation of Biochemical and FDG PET/CT Responses Following Induction Therapy in Newly Diagnosed Multiple Myeloma: A Prospective Observational Study.International journal of hematology-oncology and stem cell research · 2026Article
- Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going.Blood advances · 2025Review
- A feasibility study of [18F] FDG PET/CT radiomics in predicting high-risk cytogenetic abnormalities in multiple myeloma.EJNMMI research · 2025Article
- Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.Blood research · 2025Review
- IMPeTUs parameters correlate with clinical features in newly diagnosed multiple myeloma.European journal of radiology open · 2024Article
- Coefficient of variation and texture analysis of 18F-FDG PET/CT images for the prediction of outcome in patients with multiple myeloma.Annals of hematology · 2024Article
- Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [European journal of nuclear medicine and molecular imaging · 2024Article
- Prognostic value of visual IMPeTUs criteria and metabolic tumor burden at baseline [EJNMMI research · 2024Article
- Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care.Annals of hematology · 2024Article
- A look into the future: the role of PSMA beyond prostate cancer.European journal of nuclear medicine and molecular imaging · 2023Article
- Multitracer PET/CT with [Diagnostics (Basel, Switzerland) · 2023Article
- Current Main Topics in Multiple Myeloma.Cancers · 2023Review
- First-in-Humans Evaluation of Safety and Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Progress of modern imaging modalities in multiple myeloma.International journal of hematology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose[
methodsForty-seven patients with newly diagnosed MM underwent [
resultsMedian follow-up from baseline and follow-up PET/CT were 85.1 months and 76.7 months, respectively. The number of focal, [
conclusionSeveral parameters utilized in IMPeTUs predict PFS in MM patients, suggesting the potentially significant role of the new criteria in patient stratification and response assessment. Additional studies are warranted for the further evaluation of IMPeTUs in the direction of establishment of robust cut-off values with a prognostic significance in the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.